Nycomed CEO talks, Obama and Healthcare Reform

26 January 2010

In an exclusive interview for MeetTheBoss.tv, Hakan Bjorklund, chief executive of Switzerland-based Nycomed, explained how his style of leadership has created 11 years of solid success, and talked candidly about the pharmaceutical industry and the challenges facing him in 2010.

Mr Bjorklund confesses that Nycomed's disputes with generic manufacturers are set to continue, highlighting US President Barack Obama's health care reforms as potentially problematic. 'There is no question in my mind that not only the US government, but most of the governments today are stimulating and promoting use of generics as a way of cutting costs,' he said.

'For me it's more important to figure out a strategy that will continue to be successful rather than being upset with the way government works,' he stated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical